Dymon Asia Capital Singapore PTE. LTD. Invests $921,000 in Scholar Rock Holding Corporation $SRRK

Dymon Asia Capital Singapore PTE. LTD. purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 26,000 shares of the company’s stock, valued at approximately $921,000.

Several other institutional investors have also recently bought and sold shares of the business. Lord Abbett & CO. LLC raised its stake in shares of Scholar Rock by 86.2% in the first quarter. Lord Abbett & CO. LLC now owns 877,374 shares of the company’s stock worth $28,207,000 after acquiring an additional 406,074 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Scholar Rock by 2.5% in the first quarter. Northern Trust Corp now owns 765,280 shares of the company’s stock valued at $24,604,000 after purchasing an additional 18,753 shares in the last quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. raised its position in Scholar Rock by 145.3% in the 2nd quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 769,442 shares of the company’s stock worth $27,254,000 after purchasing an additional 455,753 shares during the last quarter. Intech Investment Management LLC lifted its holdings in Scholar Rock by 60.9% during the 1st quarter. Intech Investment Management LLC now owns 56,784 shares of the company’s stock worth $1,826,000 after buying an additional 21,483 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Scholar Rock during the 1st quarter worth $458,000. Institutional investors own 91.08% of the company’s stock.

Insider Activity

In other news, Director Srinivas Akkaraju acquired 387,414 shares of the stock in a transaction that occurred on Friday, October 3rd. The stock was acquired at an average price of $37.27 per share, for a total transaction of $14,438,919.78. Following the transaction, the director directly owned 387,414 shares in the company, valued at approximately $14,438,919.78. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, insider Mo Qatanani sold 136,462 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $45.21, for a total value of $6,169,447.02. Following the sale, the insider directly owned 108,964 shares in the company, valued at $4,926,262.44. The trade was a 55.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 143,999 shares of company stock valued at $6,411,535 in the last quarter. Company insiders own 13.30% of the company’s stock.

Scholar Rock Price Performance

Scholar Rock stock opened at $44.63 on Wednesday. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $4.55 billion, a P/E ratio of -14.17 and a beta of 0.60. The business has a 50-day moving average of $35.38 and a 200-day moving average of $34.71. Scholar Rock Holding Corporation has a 1 year low of $22.71 and a 1 year high of $46.98.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same period last year, the company earned ($0.66) EPS. On average, equities analysts anticipate that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Analyst Upgrades and Downgrades

SRRK has been the subject of a number of recent research reports. HC Wainwright dropped their target price on Scholar Rock from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, September 23rd. Leerink Partnrs raised Scholar Rock to a “strong-buy” rating in a report on Monday, September 15th. Bank of America assumed coverage on shares of Scholar Rock in a research report on Thursday, October 9th. They set a “buy” rating and a $53.00 target price on the stock. Leerink Partners started coverage on shares of Scholar Rock in a research report on Monday, September 15th. They set an “outperform” rating and a $51.00 price target for the company. Finally, Wolfe Research started coverage on shares of Scholar Rock in a research note on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price target for the company. Four analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Scholar Rock currently has a consensus rating of “Buy” and a consensus target price of $48.33.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.